Format

Send to

Choose Destination
Alzheimers Dement. 2020 Jan 15. doi: 10.1002/alz.12035. [Epub ahead of print]

Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.

Author information

1
Merck & Co., Inc., Kenilworth, New Jersey.
2
Sleep Center, Emory University School of Medicine, Atlanta, Georgia.

Abstract

INTRODUCTION:

We evaluated the clinical profile of the orexin receptor antagonist suvorexant for treating insomnia in patients with mild-to-moderate probable Alzheimer's disease (AD) dementia.

METHODS:

Randomized, double-blind, 4-week trial of suvorexant 10 mg (could be increased to 20 mg based on clinical response) or placebo in patients who met clinical diagnostic criteria for both probable AD dementia and insomnia. Sleep was assessed by overnight polysomnography in a sleep laboratory. The primary endpoint was change-from-baseline in polysomnography-derived total sleep time (TST) at week 4.

RESULTS:

Of 285 participants randomized (suvorexant, N = 142; placebo, N = 143), 277 (97%) completed the trial (suvorexant, N = 136; placebo, N = 141). At week 4, the model-based least squares mean improvement-from-baseline in TST was 73 minutes for suvorexant and 45 minutes for placebo; (difference = 28 minutes [95% confidence interval 11-45], p < 0.01). Somnolence was reported in 4.2% of suvorexant-treated patients and 1.4% of placebo-treated patients.

DISCUSSION:

Suvorexant improved TST in patients with probable AD dementia and insomnia.

KEYWORDS:

Alzheimer's disease; insomnia; randomized clinical trial; suvorexant

PMID:
31944580
DOI:
10.1002/alz.12035

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center